Kintor Pharmaceutical gets EUA for Covid drug proxalutamide in Paraguay
Kintor Pharmaceutical has secured an emergency use authorization (EUA) for proxalutamide (GT-0918) for the treatment of hospitalized patients with Covid-19 infections in Paraguay.
The EUA issued by the Ministry of Public Health and Social Welfare (MSPBS) is for the use of the nonsteroidal antiandrogen in patients admitted in MSPBS hospitals.
The Barrio Obrero hospital, which is part of the MSPBS network, became the first to use proxalutamide under the EUA. It is said to have reported promising initial results with only one inpatient out of the first 25 Covid-19 treated with proxaluatmide not able to survive.
Kintor Pharmaceutical said that such mortality rate was lower than the usual mortality rate of hospitalized Covid patients in Paraguay. Additionally, the Chinese clinical-stage biotech company said that proxalutamide has shown potential benefits in seven of the patients who initially needed high flow oxygen.
Dr. Youzhi Tong – the founder, chairman, and CEO of Kintor Pharmaceutical said: “We are delighted to see that proxalutamide is saving lives in Paraguay following the EUA from the MSPBS. We are actively exploring additional EUAs of proxalutamide in other countries and regions to help COVID-19 patients around the world.”